Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 9Terminated 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × trastuzumab biosimilar HLX02 × Clear all
NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
190 enrolled 13 charts
Breast

Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡